Should ApoE4 gene editing therapy be approached with caution when AD is accompanied by retinal neurodegenerative diseases?
Apolipoprotein E4 (ApoE4) is the strongest genetic risk factor for Alzheimer’s disease (AD), and ApoE4-directed gene editing and gene therapy have emerged as promising therapeutic strategies for AD, although they remain investigational and are not yet an established mainstream treatment. Interestingly, however, ApoE4 i...
Wen-Hua Yi, Wen Ma, Yan Dai et al.
· Frontiers in Neurology · 0 citations